NCT06553248

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of GZR4 in Chinese Patients With Type 2 Diabetes Mellitus

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Gan and Lee Pharmaceuticals, USA · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This trial is conducted in China. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of mutiple-dose GZR4 in subjects with type 2 diabetes

Conditions

• Diabetes

Interventions

Type	Name	Description
DRUG	GZR4	Administered once weekly subcutaneously (s.c., under the skin) for 6 weeks
DRUG	Insulin Degludec	Administered once daily subcutaneously (s.c., under the skin) for 6 weeks

Timeline

• Start date: 2023-03-22
• Primary completion: 2023-11-01
• Completion: 2023-11-01
• First posted: 2024-08-14
• Last updated: 2024-08-14

Locations

1 site across 1 country: China